Stock Pulse
Hologic (HOLX) reported flat Q4 2025 revenue of $1.02 billion, meeting expectations but resulting in a stock decline of 25.2% due to concerns about future growth [2]. While full-year guidance was raised, Q1 2025 guidance also met expectations, failing to excite investors [2]. The company faces headwinds including tariffs, disruptions to HIV testing programs, a strong dollar, and slowing Breast Health equipment sales, leading to reduced fiscal 2025 revenue projections [3]. However, Hologic appointed Wayde McMillan, a finance veteran, to its board of directors, which is viewed positively [3], [9], [11]. Upcoming Q2 2025 earnings are expected on May 1st [7], with projections indicating slightly lower quarterly earnings and revenue but modest full-year growth [1], [4]. Despite recent declines, HOLX's stock is considered attractively valued compared to its peers [1], [6].